ash17   140

« earlier    

Syros Pharmaceuticals 2018 Strategy | Biotech Strategy Blog
Our latest expert interview with CEO Dr Nancy Simonian is now live:

An mashup :)
JPM18  ASH17  from twitter
january 2018 by maverickny
Twitter
We all know how much

I love haikus, like at

Sciku brings us more
ASH17  from twitter_favs
december 2017 by maverickny
Twitter
Second in our series of expert interviews from features from talking about som…
ASH17  from twitter_favs
december 2017 by maverickny
Twitter
8-year follow-up data of the TWISTER STOP study: In with long-term therapy-free remissio…
ASH17  TFR  patients  CML  from twitter_favs
december 2017 by maverickny
Twitter
Part 2 of our expert interview series looks at key aggressive lymphoma data from a hard hitting interview wi…
ASH17  from twitter
december 2017 by maverickny
Critical issues in CLL | Biotech Strategy Blog
RT : First of our thought leader interviews from is now up for subs. Check it out!
ASH17  from twitter_favs
december 2017 by maverickny
Twitter
First of our thought leaders is up - what did a CLL expert really think of key data presented?…
ASH17  from twitter
december 2017 by maverickny
Twitter
⚡️ “ - Part 1” - Tweet collection - Thanks for the share
ASH17  from twitter_favs
december 2017 by maverickny
Twitter
Because nothing is as distant from walking carefree on a sunlit beach as tisagenlecleucel.
ASH17  from twitter_favs
december 2017 by maverickny
Twitter
Results of experiment with personal hashtag at - I added the hashtag to ~40 tweets total - to tag abs…
ASHVR  ASH17  from twitter_favs
december 2017 by maverickny
Twitter
DREAM(M-1) Antibody drug conjugate to BCMA .... curious to see correlation with BCMA expression !
ASH17  from twitter_favs
december 2017 by maverickny
Twitter
JULIET CR40%, ORR 53%, feasible “globally” ;)
ASH17  from twitter_favs
december 2017 by maverickny
Twitter
Armstrong: Ibrutinib+Venetoclax for relapsed CLL (CLARITY study), ORR 100%, 47% CR after 6 mos I+V
bestof  ASH17  from twitter_favs
december 2017 by maverickny
Twitter
Armstrong: global JULIET study with Novartis CD19 CAR-T, tisagenlecleucel, for NHL: ORR 53%, 40% CR,…
bestof  ASH17  from twitter_favs
december 2017 by maverickny

« earlier    

related tags

ash2017  ashsm  ashvr  bestof  cart  cartcell  cml  cordblood  dlbcl  hematology  hodgkin  imfash17  immunoonc  jpm18  juliet  leusm  lymphoma  lymsm  mmsm  mpnsm  myeloma  patients  posterhall  tcellrx  tfr  transcend  zuma 

Copy this bookmark:



description:


tags: